Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals, Inc. (SYRS) has been a biopharmaceutical company focused on developing tamibarotene, an oral, selective retinoic acid receptor alpha (RARα) agonist, for the frontline treatment of hematologic malignancies. Company news has centered on higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML) in patients whose disease exhibits RARA gene overexpression.
News coverage for Syros includes clinical trial updates from key studies such as the Phase 3 SELECT-MDS-1 trial in HR-MDS and the Phase 2 SELECT-AML-1 trial in AML. These announcements have detailed trial designs, interim analyses, complete response (CR) and CRi rates, and decisions to continue or discontinue enrollment based on prespecified futility analyses. Press releases have also discussed the safety profile of tamibarotene in combination regimens and the company’s interpretation of clinical data.
Financial and corporate updates form another important category of news for SYRS. Syros has reported quarterly financial results, described its cash position and operating expense trends, and outlined expectations for how long existing cash and cash equivalents may fund operations. The company has also provided business updates around pre-commercial activities, conference presentations, and webcast events focused on HR-MDS disease biology and the treatment landscape.
More recent news has highlighted material corporate developments, including the failure of the SELECT-MDS-1 trial to meet its primary endpoint, the resulting event of default under Syros’ loan agreement, and the company’s decision to operate as a wind-down. Additional announcements describe the Board’s approval of a voluntary delisting from Nasdaq, plans to deregister the common stock, and the sale of tamibarotene-related clinical and non-clinical assets to Rege Nephro Co., Ltd. Investors and observers can use the SYRS news stream to follow this transition from late-stage clinical development activities to an orderly wind down of operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Syros Pharmaceuticals (NASDAQ:SYRS) has initiated the randomized portion of its SELECT-AML-1 trial, with initial results expected in Q4 2023. The company received FDA Fast Track designation for tamibarotene in treating higher-risk myelodysplastic syndrome (HR-MDS). Enrollment for the SELECT-MDS-1 trial is on track for completion in Q4 2023, with pivotal data anticipated in Q3 2024. Financially, Syros reported a net loss of $4.8 million for Q4 2022, compared to a loss of $23.8 million in Q4 2021. The company maintains a robust cash position of $202.3 million, expected to fund operations through mid-2025.
Syros Pharmaceuticals (NASDAQ:SYRS) announces CEO Nancy Simonian, M.D., will participate in two investor conferences in March. The first is the Cowen 43rd Annual Health Care Conference on March 7 at 9:10 a.m. ET in Boston, focusing on Novel Oncology Targets. The second event is the Oppenheimer 32nd Annual Healthcare Conference on March 13 at 8:00 a.m. ET, conducted virtually. Syros is advancing treatments for hematologic malignancies through its clinical programs, including tamibarotene and SY-2101. For more details, visit www.syros.com.